Anlotinib plus albumin-bound paclitaxel induction-maintenance for sorafenib-refractory radioiodine-refractory differentiated thyroid cancer: A case report and review of literature

doi:10.5306/wjco.v17.i5.119615

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 5

This Article

(16)

(31)

(0)

(44)

(343)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Clin Oncol. May 24, 2026; 17(5): 119615
Published online May 24, 2026. doi: 10.5306/wjco.v17.i5.119615

Full Size Figure Download Figure

Figure 4 Diffuse pulmonary disease and pleural effusion at the time of radioiodine-refractory differentiated thyroid cancer diagnosis. A and B: A computed tomography scan performed 33 months after the third ¹³¹I treatment reveals widespread bilateral pulmonary metastases. Additionally, obstructive pneumonia within the right upper lobe and a massive right-sided pleural effusion are evident. These findings, along with the diminishing radioiodine uptake on serial ¹³¹I scans, support the diagnosis of radioiodine-refractory differentiated thyroid cancer.

Citation: Zhou CY, Ren XY, Li HH, Pan XM, Lan X, Duan D. Anlotinib plus albumin-bound paclitaxel induction-maintenance for sorafenib-refractory radioiodine-refractory differentiated thyroid cancer: A case report and review of literature. World J Clin Oncol 2026; 17(5): 119615
URL: https://www.wjgnet.com/2218-4333/full/v17/i5/119615.htm
DOI: https://dx.doi.org/10.5306/wjco.v17.i5.119615

Zhou CY, Ren XY, Li HH, Pan XM, Lan X, Duan D. Anlotinib plus albumin-bound paclitaxel induction-maintenance for sorafenib-refractory radioiodine-refractory differentiated thyroid cancer: A case report and review of literature. World J Clin Oncol 2026; 17(5): 119615 [DOI: 10.5306/wjco.v17.i5.119615]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.